Teva Pharmaceutical Industries price to free cash flow TEVA

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: 34.1×
8-year median: 21.9×
Against its 8-year history: 80th; percentile: 0 is its lowest day, 100 its highest
8-year range: 4.4× to 119×
Peer median: 35.2×

Teva Pharmaceutical Industries' price to free cash flow is 34.1× as of Oct 23, 2026.

That is above its 8-year median of 21.9×, higher than on 80% of days in the last 8 years.

Over that time it ranged from 4.4× in Dec 2018 to 119× in Nov 2021.

The median for 10 healthcare stocks of a similar size is 35.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	34.1×	28.6×	67.6×
2025	63.3×	14.7×	63.3×
2024	18.9×	13.6×	31.5×
2023	19.2×	7.8×	24.3×
2022	19.7×	13.3×	115×
2021	100×	13.1×	119×
2020	11.7×	10.7×	64.6×
2019	109×	5.0×	109×
2018	4.5×	4.4×	6.8×

Against its peers

Companies in Healthcare nearest Teva Pharmaceutical Industries' size, closest first, today.

Company	Price to free cash flow
TEVATeva Pharmaceutical Industries	34.1×
IQVIQVIA	21.1×
MDLNMedline	n/m
WATWaters	112×
IDXXIDEXX Laboratories	35.2×
AAgilent Technologies	38.5×
ONCBeOne Medicines	32.3×
HUMHumana	26.0×
EWEdwards Lifesciences	35.8×
ILMNIllumina	43.7×
BDXBecton, Dickinson and	19.8×
Peer median	35.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Teva Pharmaceutical Industries

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.